Prolor said that hGH is its proprietary biobetter version of human growth hormone.
The Phase II study was commenced to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected either weekly or twice-monthly in patients with growth hormone deficiency who currently receive daily injections of growth hormone.
Prolor is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that requires only once-weekly or bi-monthly injections, rather than the multiple injections per week required by current hGH therapy.
Abraham Havron, CEO of Prolor, said: “We are enthusiastic about the therapeutic potential of hGH-CTP based on its compelling preclinical and clinical safety and bioactivity data. Growth hormone therapy requires many years of daily injections. We hope to offer these patients a better alternative by significantly reducing the number of injections required to treat their condition.”